COP28 Climate Summit: A Moment Of Reckoning For Oil Execs, Or Just Déja Vu?
Focus will be on cutting use of fossil fuels, while carbon capture will remain controversial
‘UAE To Launch $30B Investment Fund At COP28’ – Financial Times
https://www.ft.com/content/fbe6e38b-4808-480a-ab20-9379fc2a91fd
Cidara Therapeutics To Present New Preclinical Data On Novel Dual-Acting Drug-Fc Conjugates At ESMO Immuno-Oncology Annual Congress
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of
AmpliTech Group, Inc. Discusses 2023 Revenue Projections And 2024 Technology Applications With The Stock Day Podcast
The Stock Day Podcast welcomed AmpliTech Group, Inc. (AMPG)("the Company"), a company that designs, develops, manufactures, and distributes state-of-the-art radio frequency (RF) microwave components for global satellite
Informatica Broadens Relationship With AWS, Announces Deeper Integrations Across Generative AI, AWS HealthLake And Amazon S3
Latest developments reflect a commitment to wider collaboration between the two cloud leaders and Informatica's significant AI-powered platform growth and adoption in AWS MarketplaceInformatica (NYSE:INFA), an enterprise
Perspective Therapeutics Announces First Ever Human SPECT Imaging Of Pb-212 With VMT-α-NET By Clinical Collaborators In Germany
Imaging was conducted as part of a clinical study at Technical University of Dresden in Germany Image was selected as "Image of the Month" in the European Journal of Nuclear Medicine and Molecular Imaging, November
Sagimet Biosciences Announces Oral Presentation Of Preclinical Results Of FASN Inhibitor In Combination With Semaglutide At The 7th Obesity And NASH Drug Development Summit
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, will present preclinical
Biomea Fusion Announces Acceptance Of Three Abstracts For Its Novel Menin Inhibitor Highlighting Durable Glycemic Control In Diabetes Patients At The International Conference On Advanced Technologies & Treatments For Diabetes In 2024
New clinical data from all dosing cohorts (n=62) initiated to date from the escalation portion of COVALENT-111 and long-term (26 weeks) follow-up data of the 200 mg dosed cohorts will be featured during an oral Poster
Takeda To Present Data At 65th American Society Of Hematology Annual Meeting, Demonstrating Continued Commitment To Patients With Hematologic Diseases
Company to Feature 17 Company-Sponsored and Nine Collaborative Abstracts in Oncology and HematologyHematology Presentations Include New Data from the Phase 3 and Continuation Trials Supporting the Recent U.S. FDA